Melanotan II risks: what TikTok isn't telling you

What did @stevieleaabberton actually say?

She said MT2 (melanotan II) gave her a convincing tan but came with a side effect she wasn't ready for: rapid, aggressive darkening of existing freckles and moles, plus new ones appearing. She described starting on a high dose, dosing five days a week, and says she was "not prepared for how quickly and how much it would do that." She also mentioned that ChatGPT told her the changes would fade eventually, and she passed that along without much skepticism. Her overall message was: start low, go slow, and take the mole situation seriously.

Credit where it's due. She's not selling MT2. She's not telling you to use it. She's sharing a negative experience, which is more than most peptide content on TikTok does. The freckle and mole warning is real, the dose-dependence observation is plausible, and the sunscreen nudge is genuinely good advice. But she also said some things that need unpicking.

Does the science back this up?

Yes, on the core claim. Melanotan II is a synthetic analogue of alpha-melanocyte stimulating hormone (alpha-MSH). It binds melanocortin receptors, particularly MC1R, and drives melanogenesis, the production of eumelanin in skin. That process doesn't discriminate between your baseline complexion and your existing nevi (moles) or lentigines (freckles). Everything with melanocytes gets darker.

A 2019 case series published in the Journal of the American Academy of Dermatology (Chalitsios et al.) documented multiple patients developing new or changing pigmented lesions after melanotan II use. A 2021 review in Clinical and Experimental Dermatology (Langan et al.) noted that MT2-associated melanocytic activation has been linked to rapid changes in existing nevi, some of which showed dermoscopic features that warranted biopsy. One patient in that review was diagnosed with melanoma, though causality between MT2 and malignancy remains unproven. That's not a reason to call MT2 a carcinogen. It is a reason to take changing moles seriously.

The dose-response relationship she describes, high dose equals faster, more aggressive pigmentation changes, is biologically coherent. MT2 is pharmacologically potent. This isn't a gentle nudge to your melanocytes.

What did they get wrong (or right)?

The ChatGPT detail is the part that needs calling out plainly. She said "ChatGPT says they will fade eventually" and offered that as reassurance. That's not a clinical source. There is no robust longitudinal data confirming that MT2-induced nevi changes fully reverse after cessation. Some reports suggest partial fading of diffuse tanning, but altered moles don't have a documented reversion timeline. Leaning on an AI chatbot for medical reassurance about changing moles is not a substitute for a dermatologist appointment.

She was right that higher doses correlate with more pronounced and faster pigmentation changes. She was right that sunscreen matters, though she admitted she doesn't use it, which is a problem given that UV exposure on top of MT2-primed melanocytes is an additive stimulus. She was right to flag this publicly. Most MT2 content online skips this entirely.

What she didn't address: MT2 also carries known side effects beyond pigmentation, including nausea, facial flushing, spontaneous erections in men, and blood pressure changes. These aren't rare. Omitting them from a tips-and-tricks video leaves an incomplete picture even if she wasn't trying to be comprehensive.

What should you actually know?

If you're considering MT2, the mole conversation is the one that matters most. The Skin Cancer Foundation and multiple dermatology bodies advise that any new or changing mole warrants professional evaluation. MT2 accelerates melanocytic activity. Combining that with unprotected sun exposure, which is exactly what tanning for a cruise looks like, is not a low-risk situation.

The peptide is not approved by the TGA in Australia, the FDA in the US, or the EMA in Europe. It is sold on grey markets with no quality controls on purity or concentration, which means the dose someone thinks they're taking may not be the dose they're actually taking. That makes "start low and slow" genuinely good advice, though it doesn't solve the underlying regulatory and quality problem.

If your moles or freckles change while using MT2, the right next step is a dermatologist with a dermatoscope, not ChatGPT. Dermoscopy can distinguish benign MT2-associated pigmentation changes from features that require a biopsy. Catching that difference early is the entire point.

• MT2 is not approved for cosmetic or therapeutic use in most jurisdictions.
• Changing moles during or after MT2 use should be assessed by a dermatologist, not self-monitored at home.
• ChatGPT is not a clinical reference for pharmacological side effect resolution timelines.
• Sun exposure on top of MT2 use compounds melanocytic stimulation, making sunscreen more important, not optional.